



# SAFETY DATA SHEET

Revision date: 22-Sep-2015

Version: 1.0

Page 1 of 10

## 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

### Product Identifier

**Material Name:** Ethosuximide Capsules (Greenstone LLC)

**Trade Name:** Not applicable

**Chemical Family:** Mixture

### Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

**Intended Use:** Pharmaceutical product used as anticonvulsant

### Details of the Supplier of the Safety Data Sheet

Greenstone LLC  
100 Route 206 North  
Peapack, NJ 07977  
800-435-7095

**Emergency telephone number:**  
CHEMTREC (24 hours): 1-800-424-9300

## 2. HAZARDS IDENTIFICATION

### Classification of the Substance or Mixture

#### GHS - Classification

Germ Cell Mutagenicity: Category 2

Reproductive Toxicity: Category 1B

#### EU Classification:

EU Indication of danger: Harmful

Toxic to Reproduction: Category 2

Mutagenic: Category 3

EU Risk Phrases:

R22 - Harmful if swallowed.

R61 - May cause harm to the unborn child.

R68 - Possible risk of irreversible effects.

### Label Elements

**Signal Word:** Danger

**Hazard Statements:** H360D - May damage the unborn child  
H341 - Suspected of causing genetic defects

**Precautionary Statements:** P202 - Do not handle until all safety precautions have been read and understood  
P281 - Use personal protective equipment as required  
P308 + P313 - IF exposed or concerned: Get medical attention/advice  
P405 - Store locked up  
P501 - Dispose of contents/container in accordance with all local and national regulations

## SAFETY DATA SHEET

Material Name: Ethosuximide Capsules (Greenstone LLC)  
Revision date: 22-Sep-2015

Page 2 of 10  
Version: 1.0



### Other Hazards

No data available

### Australian Hazard Classification (NOHSC):

Hazardous Substance. Non-Dangerous Goods.

### Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

## 3. COMPOSITION/INFORMATION ON INGREDIENTS

### Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Glycerin, USP	56-81-5	200-289-5	Not Listed	Not Listed	*
Ethosuximide	77-67-8	201-048-7	Xn, R22; Repr. Cat.2,R61; Mut. Cat.3,R68	Acute Tox. 4, H302; Repr. 1B, H360D; Muta. 2, H341	32-35

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Gelatin	9000-70-8	232-554-6	Not Listed	Not Listed	*
D & C yellow No. 10	8004-92-0	Not Listed	Not Listed	Not Listed	*
Sorbitol solution	50-70-4	200-061-5	Not Listed	Not Listed	*
Polyethylene glycol 400	25322-68-3	Not Listed	Not Listed	Not Listed	*
FD & C Red No. 3 (E 127)	16423-68-0	240-474-8	Not Listed	Not Listed	*

### Additional Information:

\* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

## 4. FIRST AID MEASURES

### Description of First Aid Measures

#### Eye Contact:

Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

#### Skin Contact:

Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

#### Ingestion:

Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

## SAFETY DATA SHEET

Material Name: Ethosuximide Capsules (Greenstone LLC)  
Revision date: 22-Sep-2015

Page 3 of 10  
Version: 1.0

**Inhalation:** Remove to fresh air and keep patient at rest. Seek medical attention immediately.

### Most Important Symptoms and Effects, Both Acute and Delayed

**Symptoms and Effects of Exposure:** For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.  
**Medical Conditions Aggravated by Exposure:** None known

### Indication of the Immediate Medical Attention and Special Treatment Needed

**Notes to Physician:** None

## 5. FIRE FIGHTING MEASURES

**Extinguishing Media:** Use carbon dioxide, dry chemical, or water spray.

### Special Hazards Arising from the Substance or Mixture

**Hazardous Combustion Products:** Formation of toxic gases is possible during heating or fire.

**Fire / Explosion Hazards:** Not applicable

### Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

## 6. ACCIDENTAL RELEASE MEASURES

### Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

### Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

### Methods and Material for Containment and Cleaning Up

**Measures for Cleaning / Collecting:** Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

**Additional Consideration for Large Spills:** Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

## 7. HANDLING AND STORAGE

### Precautions for Safe Handling

If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

### Conditions for Safe Storage, Including any Incompatibilities

**Storage Conditions:** Store as directed by product packaging.

**Specific end use(s):** Pharmaceutical drug product

## SAFETY DATA SHEET

Material Name: Ethosuximide Capsules (Greenstone LLC)  
Revision date: 22-Sep-2015

Page 4 of 10  
Version: 1.0

### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

#### Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

#### Glycerin, USP

Australia TWA	10 mg/m <sup>3</sup>
Belgium OEL - TWA	10 mg/m <sup>3</sup>
Czech Republic OEL - TWA	10 mg/m <sup>3</sup>
Estonia OEL - TWA	10 mg/m <sup>3</sup>
Finland OEL - TWA	20 mg/m <sup>3</sup>
France OEL - TWA	10 mg/m <sup>3</sup>
Germany (DFG) - MAK	50 mg/m <sup>3</sup>
Greece OEL - TWA	10 mg/m <sup>3</sup>
Ireland OEL - TWAs	10 mg/m <sup>3</sup>
OSHA - Final PELs - TWAs:	15 mg/m <sup>3</sup>
Poland OEL - TWA	10 mg/m <sup>3</sup>
Portugal OEL - TWA	10 mg/m <sup>3</sup>
Spain OEL - TWA	10 mg/m <sup>3</sup>

#### Polyethylene glycol 400

Austria OEL - MAKs	1000 mg/m <sup>3</sup>
Germany - TRGS 900 - TWAs	1000 mg/m <sup>3</sup>
Germany (DFG) - MAK	1000 mg/m <sup>3</sup> average molecular weight 200-600
Slovakia OEL - TWA	1000 mg/m <sup>3</sup>
Slovenia OEL - TWA	1000 mg/m <sup>3</sup>

#### Ethosuximide

Manufacturer OEL:	2mg/m <sup>3</sup>
-------------------	--------------------

#### Exposure Controls

##### Engineering Controls:

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

##### Personal Protective Equipment:

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

##### Hands:

Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

##### Eyes:

Wear safety glasses or goggles if eye contact is possible.

##### Skin:

Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

##### Respiratory protection:

If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

### 9. PHYSICAL AND CHEMICAL PROPERTIES

#### Physical State:

Capsule

#### Color:

Orange

#### Odor:

No data available.

#### Odor Threshold:

No data available.

#### Molecular Formula:

Mixture

#### Molecular Weight:

Mixture

#### Solvent Solubility:

No data available

#### Water Solubility:

No data available

## SAFETY DATA SHEET

Material Name: Ethosuximide Capsules (Greenstone LLC)  
Revision date: 22-Sep-2015

Page 5 of 10  
Version: 1.0

### 9. PHYSICAL AND CHEMICAL PROPERTIES

**pH:** No data available.  
**Melting/Freezing Point (°C):** No data available  
**Boiling Point (°C):** No data available.  
**Partition Coefficient: (Method, pH, Endpoint, Value)**  
**D & C yellow No. 10**  
No data available  
**FD & C Red No. 3 (E 127)**  
No data available  
**Polyethylene glycol 400**  
No data available  
**Glycerin, USP**  
No data available  
**Sorbitol solution**  
No data available  
**Gelatin**  
No data available  
**Ethosuximide**  
No data available  
**Decomposition Temperature (°C):** No data available.  
  
**Evaporation Rate (Gram/s):** No data available  
**Vapor Pressure (kPa):** No data available  
**Vapor Density (g/ml):** No data available  
**Relative Density:** No data available  
**Viscosity:** No data available

#### Flammability:

<b>Autoignition Temperature (Solid) (°C):</b>	No data available
<b>Flammability (Solids):</b>	No data available
<b>Flash Point (Liquid) (°C):</b>	No data available
<b>Upper Explosive Limits (Liquid) (% by Vol.):</b>	No data available
<b>Lower Explosive Limits (Liquid) (% by Vol.):</b>	No data available

### 10. STABILITY AND REACTIVITY

**Reactivity:** No data available  
**Chemical Stability:** Stable under normal conditions of use.  
**Possibility of Hazardous Reactions**  
**Oxidizing Properties:** No data available  
**Conditions to Avoid:** Fine particles (such as dust and mists) may fuel fires/explosions.  
**Incompatible Materials:** As a precautionary measure, keep away from strong oxidizers  
**Hazardous Decomposition Products:** No data available

### 11. TOXICOLOGICAL INFORMATION

#### Information on Toxicological Effects

**General Information:** The information included in this section describes the potential hazards of the individual ingredients.  
**Short Term:** May be harmful if swallowed. (based on animal data)

## SAFETY DATA SHEET

Material Name: Ethosuximide Capsules (Greenstone LLC)  
Revision date: 22-Sep-2015

Page 6 of 10  
Version: 1.0

### 11. TOXICOLOGICAL INFORMATION

**Known Clinical Effects:** Effects reported during clinical use included vomiting and diarrhea. Central nervous system effects such as dizziness, headache, insomnia, irritability and weakness have also been reported. Clinical use of this drug has caused decreased blood cell count, increased eosinophils in blood or tissue (eosinophilia), skin rash, Stevens Johnson Syndrome (epidermal necrosis and exfoliative dermatitis) May cause adverse effects on the developing fetus.

#### Acute Toxicity: (Species, Route, End Point, Dose)

##### **D & C yellow No. 10**

Rat Oral LD50 2000 mg/kg

##### **FD & C Red No. 3 (E 127)**

Rat Oral LD50 1840 mg/kg

Mouse Oral LD50 1264mg/kg

##### **Glycerin, USP**

Mouse Oral LD50 4090 mg/kg

Rat Oral LD50 12.6 g/kg

Rabbit Dermal LD50 > 10 g/kg

Rat Inhalation LC50 1hr > 570 mg/m<sup>3</sup>

Rat Dermal LD 50 > 21.9 g/kg

##### **Sorbitol solution**

Rat Oral LD50 15,900 mg/kg

Mouse Oral LD50 17,800mg/kg

##### **Ethosuximide**

Mouse Oral LD50 1530 mg/kg

Rat Oral LD50 1950mg/kg

Mouse Intravenous LD50 780mg/kg

Mouse Intravenous LD50 1070mg/kg

**Acute Toxicity Comments:** A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

#### Irritation / Sensitization: (Study Type, Species, Severity)

##### **Polyethylene glycol 400**

Eye Irritation Rabbit Mild

Skin Irritation Rabbit Mild

##### **Glycerin, USP**

Eye Irritation Rabbit Mild

#### Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

##### **Ethosuximide**

3 Month(s) Dog Oral 100 mg/kg/day LOAEL Liver

26 Week(s) Rat Oral 676 mg/kg/day NOAEL None identified

26 Week(s) Dog Oral 100 mg/kg/day NOAEL None identified

26 Week(s) Monkey Oral 200 mg/kg/day NOAEL None identified

1 Year(s) Mouse Oral 136 mg/kg/day LOAEL Liver

## SAFETY DATA SHEET

Material Name: Ethosuximide Capsules (Greenstone LLC)  
Revision date: 22-Sep-2015

Page 7 of 10  
Version: 1.0

### 11. TOXICOLOGICAL INFORMATION

#### Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

##### **Ethosuximide**

Embryo / Fetal Development	Rat	60 mg/kg/day	LOEL	Teratogenic
2 Generation Reproductive Toxicity	Rat	Oral	0.2 %	LOAEL Not Teratogenic, Embryotoxicity
Embryo / Fetal Development	Mouse	Oral	60 mg/kg/day	LOAEL Teratogenic
Prenatal & Postnatal Development	Mouse	Oral	50 mg/mL	NOAEL Embryotoxicity, Reproductive toxicity, Developmental toxicity

#### Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

##### **Ethosuximide**

<i>In Vitro</i> Cytogenetics	Human	Negative
<i>In Vivo</i> Micronucleus	Mouse Bone Marrow	Positive

**Carcinogen Status:** None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

### 12. ECOLOGICAL INFORMATION

**Environmental Overview:** Environmental properties have not been investigated. Releases to the environment should be avoided.

#### **Toxicity:**

#### Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

##### **Glycerin, USP**

<i>Oncorhynchus mykiss</i> (Rainbow Trout)	LC50	96 Hours	50 mg/L
<i>Daphnia magna</i> (Water Flea)	EC50	24 Hours	>500 mg/L

**Aquatic Toxicity Comments:** A greater than symbol (>) indicates that aquatic toxicity was not observed at the maximum dose tested.

**Persistence and Degradability:** No data available

**Bio-accumulative Potential:** No data available

**Mobility in Soil:** No data available

### 13. DISPOSAL CONSIDERATIONS

**Waste Treatment Methods:** Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

## SAFETY DATA SHEET

Material Name: Ethosuximide Capsules (Greenstone LLC)  
Revision date: 22-Sep-2015

Page 8 of 10  
Version: 1.0

### 14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

### 15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

#### Canada - WHMIS: Classifications

##### WHMIS hazard class:

Class D, Division 2, Subdivision A



#### Glycerin, USP

CERCLA/SARA 313 Emission reporting

Not Listed

California Proposition 65

Not Listed

Inventory - United States TSCA - Sect. 8(b)

Present

Australia (AICS):

Present

REACH - Annex V - Exemptions from the obligations of Register:

Present if not chemically modified, except they meet the criteria for classification as dangerous according to Directive 67/548/EEC, except those only classified as flammable [R10], as a skin irritant [R38] or as an eye irritant [R36], except they are persistent, bioaccumulative, and toxic or very persistent and very bioaccumulative in accordance with the criteria set out in Annex XIII, except they were identified in accordance with Article 59[1] at least two years previously as substances giving rise to an equivalent level of concern

EU EINECS/ELINCS List

200-289-5

#### Gelatin

CERCLA/SARA 313 Emission reporting

Not Listed

California Proposition 65

Not Listed

Inventory - United States TSCA - Sect. 8(b)

Present

Australia (AICS):

Present

EU EINECS/ELINCS List

232-554-6

#### D & C yellow No. 10

CERCLA/SARA 313 Emission reporting

Not Listed

California Proposition 65

Not Listed

Inventory - United States TSCA - Sect. 8(b)

Present

Australia (AICS):

Present



## SAFETY DATA SHEET

Material Name: Ethosuximide Capsules (Greenstone LLC)  
Revision date: 22-Sep-2015

Page 9 of 10  
Version: 1.0

### 15. REGULATORY INFORMATION

EU EINECS/ELINCS List	Not Listed
<b>Sorbitol solution</b>	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	200-061-5
<b>Polyethylene glycol 400</b>	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 3
EU EINECS/ELINCS List	Not Listed
<b>FD &amp; C Red No. 3 (E 127)</b>	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	240-474-8
<b>Ethosuximide</b>	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 4
EU EINECS/ELINCS List	201-048-7

### 16. OTHER INFORMATION

#### Text of CLP/GHS Classification abbreviations mentioned in Section 3

Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed  
Reproductive toxicity-Cat.1B; H360D - May damage the unborn child  
Germ cell mutagenicity-Cat.2; H341 - Suspected of causing genetic defects

Mutagenic: Category 3  
Toxic to Reproduction: Category 2  
Xn - Harmful

R22 - Harmful if swallowed.  
R61 - May cause harm to the unborn child.  
R68 - Possible risks of irreversible effects.

**Data Sources:** The data contained in this SDS may have been gathered from confidential internal sources, raw material suppliers, or from the published literature.

## SAFETY DATA SHEET

**Material Name:** Ethosuximide Capsules (Greenstone LLC)  
**Revision date:** 22-Sep-2015

**Page 10 of 10**  
**Version: 1.0**

---

**Revision date:** 22-Sep-2015  
Product Stewardship Hazard Communication  
**Prepared by:** Global Environment, Health, and Safety Operations

It is believed that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without a warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time

**End of Safety Data Sheet**